Skip to content
Home/Companies/Biotech/STORM Therapeutics
STORM Therapeutics

STORM Therapeutics

Biotech·UK·Active·10yr hold
Entry
2016
Hold
10yr
Status
Active

Who owns STORM Therapeutics?

STORM Therapeutics is a British Biotech company, currently owned by Cambridge Innovation Capital since 2016.

Hand-verified · updated 2026-06-21

Open JSON · CC-BY
Cambridge Innovation Capital
Investor
Cambridge Innovation Capital
CIC Fund I · 2013 · VC

Key facts

HQUK
SectorBiotech
StatusActive
Websitewww.stormtherapeutics.com

More from CIC Fund I

Other portfolio companies in the same fund.

Seldon
Seldon
Exited 2026
AI/MLUK· 2020
to TrueFoundry
Gyroscope Therapeutics
Gyroscope Therapeutics
Exited 2021
BiotechUK· 2019
to Novartis
PredictImmune
Exited 2024
HealthTechUK· 2019
Sense Biodetection
Sense Biodetection
Exited 2023
MedTechUK· 2019
to Sherlock Biosciences
Audio Analytic
Exited 2022
AI/MLUK· 2017
to Meta
Cytora
Cytora
Exited 2025
InsurTechUK· 2017
to Applied Systems

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns STORM Therapeutics?

STORM Therapeutics is currently owned by Cambridge Innovation Capital, through CIC Fund I, since 2016.

When did Cambridge Innovation Capital acquire STORM Therapeutics?

Cambridge Innovation Capital acquired STORM Therapeutics in 2016.

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue